Prediction of Pregnancy-Induced Changes in Secretory and Total Renal Clearance of Drugs Transported by Organic Anion Transporters.

Pregnancy can significantly change the pharmacokinetics of drugs, including those renally secreted by organic anion transporters (OATs). Quantifying these changes in pregnant women is logistically and ethically challenging. Hence, predicting the in vivo plasma renal secretory clearance (CL _sec ) and renal CL (CL _renal ) of OAT drugs in pregnancy is important to design correct dosing regimens of OAT drugs. Here, we first quantified the fold-change in renal OAT activity in pregnant versus nonpregnant individual using available selective OAT probe drug CL _renal data (training dataset; OAT1: tenofovir, OAT2: acyclovir, OAT3: oseltamivir carboxylate). The fold-change in OAT1 activity during the 2 ^nd and 3 ^rd trimester was 2.9 and 1.0 compared with nonpregnant individual, respectively. OAT2 activity increased 3.1-fold during the 3 ^rd trimester. OAT3 activity increased 2.2, 1.7 and 1.3-fold during the 1 ^st , 2 ^nd , and 3 ^rd trimester, respectively. Based on these data, we predicted the CL _sec , CL _renal and total clearance ((CL _total ) of drugs in pregnancy, which are secreted by multiple OATs (verification dataset; amoxicillin, pravastatin, cefazolin and ketorolac, R -ketorolac, S -ketorolac). Then, the predicted clearances (CLs) were compared with the observed values. The predicted/observed CL _sec , CL _renal , and CL _total of drugs in pregnancy of all verification drugs were within 0.80-1.25 fold except for CL _sec of amoxicillin in the 3 ^rd trimester (0.76-fold) and cefazolin in the 2 ^nd trimester (1.27-fold). Overall, we successfully predicted the CL _sec , CL _renal , and CL _total of drugs in pregnancy that are renally secreted by multiple OATs. This approach could be used in the future to adjust dosing regimens of renally secreted OAT drugs which are administered to pregnant women. SIGNIFICANCE STATEMENT: To the authors' knowledge, this is the first report to successfully predict renal secretory clearance and renal clearance of multiple OAT substrate drugs during pregnancy. The data presented here could be used in the future to adjust dosing regimens of renally secreted OAT drugs in pregnancy. In addition, the mechanistic approach used here could be extended to drugs transported by other renal transporters.
Competing Interests: The authors have no conflicts of interest to declare.
(Copyright © 2021 by The American Society for Pharmacology and Experimental Therapeutics.)